The unlikely spread among cattle and one dairy worker has scientists looking through the data to better understand this spillover. They say the risk to humans hinges on whether the virus can evolve in key ways to better infect mammals.
A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday.
Recent Comments